通过共同靶向MCL1增强维奈克拉在急性髓系白血病中的活性
该研究探讨维奈克拉与化疗药联合及双靶向BCL-2和MCL1的策略,发现维奈克拉与阿糖胞苷和伊达比星协同增强抗白血病效果且呈TP53依赖;高剂量伊达比星可独立于TP53抑制MCL1并诱导Bak依赖性细胞死亡;双靶向BCL-2和MCL1延长荷白血病小鼠生存,支持进一步研究维奈克拉联合标准化疗及直接MCL1抑制剂。
要点
- 维奈克拉与阿糖胞苷和伊达比星协同增强抗白血病效果,该作用呈TP53依赖。
- 高剂量伊达比星可独立于TP53抑制MCL1并诱导Bak依赖性细胞死亡。
- 双靶向BCL-2和MCL1可延长荷白血病小鼠生存,单靶向则不能。
核心结论
- 研究结果支持进一步研究维奈克拉联合标准化疗(包括强化剂量伊达比星)。
- 未来还应研究维奈克拉联合直接MCL1抑制剂作为无化疗方案。
研究设计与样本
- 临床前研究,使用可诱导载体和维奈克拉差异靶向抗凋亡BCL-2家族成员,并在荷白血病小鼠中评估生存。
主要发现
- 维奈克拉与阿糖胞苷和伊达比星协同增强抗白血病效果,且呈TP53依赖。
- TP53缺陷损害对维奈克拉联合化疗的敏感性,但更高剂量伊达比星能抑制MCL1并独立于TP53诱导细胞死亡。
- 高剂量伊达比星所致细胞死亡依赖促凋亡蛋白Bak。
- 更高剂量伊达比星联合维奈克拉能部分克服Bak缺陷细胞的耐药。
- BCL-2和MCL1是调节急性髓系白血病细胞生存的关键且互补蛋白;双靶向BCL-2和MCL1(而非任一单靶向)延长荷白血病小鼠生存。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted therapies are frequently combined with standard cytotoxic drugs to enhance clinical response. Targeting the B-cell lymphoma 2 (BCL-2) family of proteins is an attractive option to combat chemoresistance in leukemia. Preclinical and clinical studies indicate modest single-agent activity with selective BCL-2 inhibitors (for example, venetoclax). We show that venetoclax synergizes with cytarabine and idarubicin to increase antileukemic efficacy in a TP53-dependent manner. Although TP53 deficiency impaired sensitivity to combined venetoclax and chemotherapy, higher-dose idarubicin was able to suppress MCL1 and induce cell death independently of TP53. Consistent with an MCL1-specific effect, cell death from high-dose idarubicin was dependent on pro-apoptotic Bak. Combining higher-dose idarubicin with venetoclax was able to partially overcome resistance in Bak-deficient cells. Using inducible vectors and venetoclax to differentially target anti-apoptotic BCL-2 family members, BCL-2 and MCL1 emerged as critical and complementary proteins regulating cell survival in acute myeloid leukemia. Dual targeting of BCL-2 and MCL1, but not either alone, prolonged survival of leukemia-bearing mice. In conclusion, our findings support the further investigation of venetoclax in combination with standard chemotherapy, including intensified doses of idarubicin. Venetoclax should also be investigated in combination with direct inhibitors of MCL1 as a chemotherapy-free approach in the future.
引用
- Teh TC, Nguyen NY, Moujalled DM, et al. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia. 2017. PMID: 28751770. doi:10.1038/leu.2017.243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。